Effect of sufentanil on laryngeal mask placement ED50 and ED95 induced by remimazolam general anesthesia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200062668

Enrollment

Unknown

Registered

2022-08-15

Start date

2022-08-20

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

general anesthesia

Interventions

R group:induced by remimazolam general anesthesia

SR group:induced by sufentanil and remimazolalm

Eligibility

Sex/Gender

Male

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Aged 18-64 years, gender unlimited, ASA I-II, BMI 18-30 kg/m2.

Exclusion criteria

Exclusion criteria: 1. Known benzodiazepine or dairy allergies; 2. Patients with a history of bronchial asthma, myasthenia gravis, schizophrenia, and severe depression, patients with predictable intubation difficulties; 3. SBP >= 160mmHg, DBP >= 95mmHg, HR >= 110 beats/min or <=50 beats/min.

Design outcomes

Primary

Measure	Time frame
Induction success rate of general anesthesia;MOAA/S score <= 1 time;	—

Secondary

Measure	Time frame
systolic pressure;diastolic pressure;mean arterial pressure;heart rate;	—

Countries

China

Contacts

Public ContactZhao Gang

Zhuji People's Hospital

zg991337@126.com+86 13735215515

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026